Cortical amyloid levels in the brain, a marker of preclinical Alzheimer disease, was tested for its associated with self-reported loneliness in a new article published online by JAMA Psychiatry.
Alzheimer disease (AD) is a process that moves through preclinical, mild cognitive impairment and dementia stages before it leads to progressive neuropsychiatric, cognitive and functional declines.
Nancy J. Donovan, M.D., of Brigham and Women's Hospital and Harvard Medical School, Boston, and coauthors used imaging as a measure of cortical amyloid levels in the brain and a loneliness scale to indicate levels of loneliness. The study included 43 women and 36 men with an average age of about 76.
The authors report higher cortical amyloid levels were associated with greater loneliness after controlling for age, sex, APOE4, socioeconomic status, depression, anxiety and social network.
Participants in the amyloid-positive group were 7.5 times more likely to be classified as lonely then nonlonely compared with individuals in the amyloid-negative group. The association between high amyloid levels and loneliness also was stronger in APOE4 carriers than in noncarriers, according to the results.
Limitations of the study include the demographic profile of the participants who had high intelligence and educational attainment but limited racial and socioeconomic diversity. The participants also had better mental and physical health.
"We report a novel association of loneliness and cortical amyloid burden in cognitively normal adults and present evidence for loneliness as a neuropsychiatric symptom relevant to preclinical AD. This work will inform new research into the neurobiology of loneliness and other socioemotional changes in late life and may enhance early detection and intervention research in AD," the study concludes.